The global PCR technologies Market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0% from 2022 to 2027.
Polymerase chain reaction (PCR) is a well-established technique used for the in vitro amplification of a given nucleotide (such as DNA). This technique is used to prepare multiple copies of a gene and to synthesize a large number of DNA molecules from a given DNA sample. This is done by separating the two strands of the DNA, marking its location with a primer, and using a DNA polymerase enzyme to synthesize and assemble a copy of the gene alongside a template.
To know about the assumptions considered for the study download the pdf brochure
Growth in this market is largely driven by factors such rising incidence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and increasing investments. On the other hand, the high instrument costs—especially that of dPCR—and the technical limitations of PCR are expected to limit market growth to a certain extent in the coming years.
The competitive landscape includes the analysis of the key growth strategies adopted by major players between 2018–2022 to expand their global presence and increase their market shares in the point of care market. The key growth strategies adopted by the top players in the market include product launches & approvals, mergers & acquisitions, collaborations, partnerships, and agreements. Product approvals and launches were the most widely adopted organic growth strategies by market players in the last three years to garner a larger share of the market. The point of care market is dominated Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan)
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is one of the leading players in the field of healthcare and life science research. The company possesses a robust product portfolio in the PCR segment and a strong market presence globally, with sales and distribution networks in more than 50 countries. It focuses on strengthening its position in this market by adopting various growth strategies (such as product launches & approvals, acquisitions, and partnerships). The company mainly focuses on launching new products and strategic acquisitions to strengthen its market position and expand its product portfolio with technologically advanced products. The company also focuses on research partnerships with leading organizations to strengthen its research and product development capabilities in the field of dPCR and qPCR technologies.
F. HOFFMANN-LA ROCHE LTD.
Roche Diagnostics has established itself as a key player in the PCR technologies market. Roche Diagnostics strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for this growing market. To remain competitive in the market, the company also focuses on inorganic growth strategies such as agreements and acquisitions. These strategies enable it to expand its point-of-care molecular testing portfolio. The company’s focus on product integration, through the launch of holistic and user-friendly products, will help it to further strengthen its presence in the PCR market.
Bio-Rad Laboratories is one of the leading players in the field of disease diagnostics and laboratory products. The company has a noteworthy presence in the PCR industry and a wide geographic presence in major markets (such as the US, Germany, Japan, China, India, and Brazil). Bio-Rad is involved in the development, manufacturing, and marketing of more than 5,000 reagents, apparatus, and laboratory instruments (including qPCR and dPCR products). The acquisition of RainDance Technologies in 2017 enabled Bio-Rad to strengthen its position in the dPCR market by leveraging RainDance’s droplet microfluid technology for novel product development and product portfolio expansion.
From 2018 to 2021, Bio-Rad Laboratories witnessed a steady rise in its profit margin and the annual revenue of its Life Sciences segment. This growth was mainly driven by the recent commercialization of its dPCR and qPCR instruments, assays, and software. The company is focused on the development and commercialization of innovative dPCR and qPCR products that are highly efficient and can be used for clinical diagnosis. In the last three years, Bio-Rad has launched several PCR products to meet the growing market demand for novel clinical diagnostic products by offering innovative products to its customers from the research and clinical fields.
PCR Technologies Market by Technique (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End User (Academia, Pharma-Biotech, Applied) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE